Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Jakse

Showing results (151-160 of 229) with videos related to

Pageof 23
Sort By:
Urologia Internationalis|January 1, 1997
Prostate-specific antigen immunoreactivity in spinal fluidJ M Wolff, H Borchers, O Kunitz, et al.
Urologia Internationalis|June 30, 1998
Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasiaJ M Wolff, H Borchers, B Brehmer, et al.
Anticancer Research|September 2, 1999
Cytokeratin markers in patients with prostatic diseasesJ M Wolff, H Borchers, B Brehmer, et al.
Anticancer Research|May 1, 2001
Are age-specific reference ranges for prostate specific antigen population specific?J M Wolff, B Brehmer, H Borchers, et al.
Urological Research|January 1, 1994
Measurement of BBN-induced alterations in rat urothelium by electron microscopic X-ray microanalysisR Sikora, D Rohde, W G Burchard, et al.
European Urology|January 1, 1990
Evaluation of tumor response in patients with bladder cancer undergoing combined radiotherapy and chemotherapyG Jakse, D zur Nedden, G Hellweg, et al.
Journal of Endourology|December 1, 1996
Early detection of infected ureteral obstruction after SWL employing C-reactive proteinJ M Wolff, W Boeckmann, P Mattelaer, et al.
Aktuelle Urologie|January 30, 2009
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]K Miller, L Bergmann, E Jäger, et al.
European Urology|January 1, 1997
5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trialJ Breul, G Jakse, G Forster, et al.
Histopathology|August 25, 1999
Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3pL Füzesi, B Gunawan, F Bergmann, et al.
Pageof 23

Showing results (151-160 of 229) with videos related to

Sort By:
Pageof 23
Urologia Internationalis|January 1, 1997
Prostate-specific antigen immunoreactivity in spinal fluidJ M Wolff, H Borchers, O Kunitz, et al.
Urologia Internationalis|June 30, 1998
Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasiaJ M Wolff, H Borchers, B Brehmer, et al.
Anticancer Research|September 2, 1999
Cytokeratin markers in patients with prostatic diseasesJ M Wolff, H Borchers, B Brehmer, et al.
Anticancer Research|May 1, 2001
Are age-specific reference ranges for prostate specific antigen population specific?J M Wolff, B Brehmer, H Borchers, et al.
Urological Research|January 1, 1994
Measurement of BBN-induced alterations in rat urothelium by electron microscopic X-ray microanalysisR Sikora, D Rohde, W G Burchard, et al.
European Urology|January 1, 1990
Evaluation of tumor response in patients with bladder cancer undergoing combined radiotherapy and chemotherapyG Jakse, D zur Nedden, G Hellweg, et al.
Journal of Endourology|December 1, 1996
Early detection of infected ureteral obstruction after SWL employing C-reactive proteinJ M Wolff, W Boeckmann, P Mattelaer, et al.
Aktuelle Urologie|January 30, 2009
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]K Miller, L Bergmann, E Jäger, et al.
European Urology|January 1, 1997
5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trialJ Breul, G Jakse, G Forster, et al.
Histopathology|August 25, 1999
Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3pL Füzesi, B Gunawan, F Bergmann, et al.
Pageof 23